| Popis: |
Introduction. There is a trend towards an increase in the number of people with long-term consequences of COVID-19, including those with psychocognitive dysfunction, which is probably a manifestation of the “post-COVID-19 condition”.Target. To conduct a comparative assessment of the psychocognitive status in comorbid elderly patients, depending on the presence of post-COVID syndrome.Methods and materials. In an observational analytical cohort study, 223 patients with atrial fibrillation and comorbidity (ischemic heart disease, arterial hypertension, obesity, type II diabetes mellitus) aged 60-74 years, without a history of SARS-CoV-2 infection and with a history of documented confirmed SARS- CoV-2 infection with post-COVID syndrome (PCS). The patients were divided into 2 groups: I - 123 patients without a history of a new coronavirus infection COVID-19 and II - 110 patients with a past SARS-CoV-2 infection. A general clinical study of patients was carried out; assessment of psychocognitive impairments using the SPMSQ and HADS questionnaires. Statistical data processing was carried out in the RStudio program (version 2021.09.2 Build 382 — © 2009–2022 RStudio, Inc., USA, URL https://www.rstudio.com/) in the R language (version 4.0.2, URL https: //www.R-project.org/).Results. It was found that anxiety-depressive syndrome (ADS) with concomitant comorbid pathology was observed in 49-61% of cases, with a higher frequency in patients with Сovid-19. Subclinical anxiety - in 26% without covid-19 and 27% of patients with PCS; clinically expressed anxiety in 13% of patients in both groups. When assessing cognitive function, it was found that in patients with PCS, dysfunction was significantly more common (p=0.007); at the same time, mild cognitive impairment in the compared groups did not differ statistically significantly, but the number of patients in the group with PCD prevailed, moderate cognitive impairment was found in a greater number in patients with PCD - 22% vs. 8% (p = 0.005), severe cognitive impairment was detected in persons with PCS - 2%. Evaluation in individual clinical comorbid groups showed a significant difference in patients with type 2 diabetes, so in patients without PKD - 51% compared with 28% with PKD (p = 0.012).Conclusion. The post-COVID-19 future remains uncertain, therefore an assessment of its long-term consequences in comorbid patients is needed, which can be achieved by repurposing or initiating large cohort studies to focus not only on the long-term consequences of SARS-CoV-2 infection, but also on acquired psychocognitive dysfunction. |
